个人中心 - 老虎社区

Terencecino

IP属地：未知

帖子 · 8帖子 · 8
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- TerencecinoTerencecino
  ·2021-07-01
  $Marin(MRIN)$New AMC[Happy]
  102 评论
  1
  分享
  举报
- TerencecinoTerencecino
  ·2021-06-23
  $Orphazyme A/S(ORPH)$To the moon
  170 评论
  1
  分享
  举报
- TerencecinoTerencecino
  ·2021-06-22
  Awesome
  Clover Health rally Tuesday, rose over 17% in morning trading
  (June 22) Clover Health rally Tuesday, rose over 17% in morning trading.
  Clover Health rally Tuesday, rose over 17% in morning trading
  48 评论
  点赞
  分享
  举报
- TerencecinoTerencecino
  ·2021-06-20
  Power
  AstraZeneca must use Britain's plant if needed to meet EU's vaccine commitments - EU lawyer
  June 18 (Reuters) - AstraZeneca must deliver COVID-19 vaccines to the European Union also from a fac
  AstraZeneca must use Britain's plant if needed to meet EU's vaccine commitments - EU lawyer
  215 评论
  1
  分享
  举报
- TerencecinoTerencecino
  ·2021-06-18
  Yeah...good!
  Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich
  There are better options for investors looking to profit from potential Alzheimer's disease treatmen
  Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich
  230 评论
  点赞
  分享
  举报
- TerencecinoTerencecino
  ·2021-06-08
  To the moon!
  97 评论
  点赞
  分享
  举报
- TerencecinoTerencecino
  ·2021-06-08
  Well said
  Clover Health Emerges As Top WallStreetBets Interest As It Outperforms AMC, BlackBerry Stocks On Monday
  Clover Health Investments Corp emerged as the most discussed name on r/WallStreetBets, or WSB, a pop
  Clover Health Emerges As Top WallStreetBets Interest As It Outperforms AMC, BlackBerry Stocks On Monday
  92 评论
  2
  分享
  举报
- TerencecinoTerencecino
  ·2021-06-08
  $AMC Entertainment(AMC)$up up up
  180 评论
  3
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582621734355797","uuid":"3582621734355797","gmtCreate":1619538889200,"gmtModify":1704447497399,"name":"Terencecino","pinyin":"terencecino","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/c10e56060ac2fd657f71b3866495a427","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":20,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.54%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.26","exceedPercentage":"80.58%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":158592370,"gmtCreate":1625154306890,"gmtModify":1631885418656,"author":{"id":"3582621734355797","authorId":"3582621734355797","name":"Terencecino","avatar":"https://static.tigerbbs.com/c10e56060ac2fd657f71b3866495a427","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582621734355797","authorIdStr":"3582621734355797"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>New AMC[Happy]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>New AMC[Happy]&nbsp;","text":"$Marin(MRIN)$New AMC[Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158592370","isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121867621,"gmtCreate":1624459110363,"gmtModify":1631884829212,"author":{"id":"3582621734355797","authorId":"3582621734355797","name":"Terencecino","avatar":"https://static.tigerbbs.com/c10e56060ac2fd657f71b3866495a427","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582621734355797","authorIdStr":"3582621734355797"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>To the moon","listText":"<a href=\"https://laohu8.com/S/ORPH\">$Orphazyme A/S(ORPH)$</a>To the moon","text":"$Orphazyme A/S(ORPH)$To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121867621","isVote":1,"tweetType":1,"viewCount":170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129682509,"gmtCreate":1624371039301,"gmtModify":1634007120557,"author":{"id":"3582621734355797","authorId":"3582621734355797","name":"Terencecino","avatar":"https://static.tigerbbs.com/c10e56060ac2fd657f71b3866495a427","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582621734355797","authorIdStr":"3582621734355797"},"themes":[],"htmlText":"Awesome","listText":"Awesome","text":"Awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129682509","repostId":"1163697674","repostType":4,"repost":{"id":"1163697674","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624370501,"share":"https://ttm.financial/m/news/1163697674?lang=&edition=full","pubTime":"2021-06-22 22:01","market":"us","language":"en","title":"Clover Health rally Tuesday, rose over 17% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1163697674","media":"Tiger Newspress","summary":"(June 22) Clover Health rally Tuesday, rose over 17% in morning trading.","content":"<p>(June 22)&nbsp;Clover Health rally Tuesday, rose over 17% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/c8220041ca1b41ddcd04ef608958edf3\" tg-width=\"658\" tg-height=\"477\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Health rally Tuesday, rose over 17% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Health rally Tuesday, rose over 17% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-22 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 22)&nbsp;Clover Health rally Tuesday, rose over 17% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/c8220041ca1b41ddcd04ef608958edf3\" tg-width=\"658\" tg-height=\"477\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163697674","content_text":"(June 22) Clover Health rally Tuesday, rose over 17% in morning trading.","news_type":1,"symbols_score_info":{"CLOV":0.9}},"isVote":1,"tweetType":1,"viewCount":48,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164362886,"gmtCreate":1624172670345,"gmtModify":1631888657934,"author":{"id":"3582621734355797","authorId":"3582621734355797","name":"Terencecino","avatar":"https://static.tigerbbs.com/c10e56060ac2fd657f71b3866495a427","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582621734355797","authorIdStr":"3582621734355797"},"themes":[],"htmlText":"Power","listText":"Power","text":"Power","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164362886","repostId":"2144771068","repostType":4,"repost":{"id":"2144771068","kind":"news","pubTimestamp":1624026418,"share":"https://ttm.financial/m/news/2144771068?lang=&edition=full","pubTime":"2021-06-18 22:26","market":"us","language":"en","title":"AstraZeneca must use Britain's plant if needed to meet EU's vaccine commitments - EU lawyer","url":"https://stock-news.laohu8.com/highlight/detail?id=2144771068","media":"Reuters","summary":"June 18 (Reuters) - AstraZeneca must deliver COVID-19 vaccines to the European Union also from a fac","content":"<p>June 18 (Reuters) - AstraZeneca must deliver COVID-19 vaccines to the European Union also from a factory in Britain if it is needed to meet its commitments with the EU, a judge ruled on Friday, according to a lawyer representing the EU.</p>\n<p>The company had said it could not immediately deliver to the EU doses from an Oxford Biomedica factory in Britain because it had to supply the United Kingdom first.</p>\n<p>The EU lawyer said the judge decided that that factory must be used for EU supplies. However, AstraZeneca could meet its commitments with the EU without using that factory.</p>\n<p>The company is not obliged to deliver doses by a timetable in the contract until the end of June, but must still deliver a total of 300 million doses to the EU, the judge ruled. (Reporting by Francesco Guarascio @fraguarascio, editing by Louise Heavens)</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca must use Britain's plant if needed to meet EU's vaccine commitments - EU lawyer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca must use Britain's plant if needed to meet EU's vaccine commitments - EU lawyer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/astrazeneca-must-britains-plant-needed-132658433.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>June 18 (Reuters) - AstraZeneca must deliver COVID-19 vaccines to the European Union also from a factory in Britain if it is needed to meet its commitments with the EU, a judge ruled on Friday, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/astrazeneca-must-britains-plant-needed-132658433.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"https://finance.yahoo.com/news/astrazeneca-must-britains-plant-needed-132658433.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2144771068","content_text":"June 18 (Reuters) - AstraZeneca must deliver COVID-19 vaccines to the European Union also from a factory in Britain if it is needed to meet its commitments with the EU, a judge ruled on Friday, according to a lawyer representing the EU.\nThe company had said it could not immediately deliver to the EU doses from an Oxford Biomedica factory in Britain because it had to supply the United Kingdom first.\nThe EU lawyer said the judge decided that that factory must be used for EU supplies. However, AstraZeneca could meet its commitments with the EU without using that factory.\nThe company is not obliged to deliver doses by a timetable in the contract until the end of June, but must still deliver a total of 300 million doses to the EU, the judge ruled. (Reporting by Francesco Guarascio @fraguarascio, editing by Louise Heavens)","news_type":1,"symbols_score_info":{"AZN":0.9}},"isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162932304,"gmtCreate":1624030679108,"gmtModify":1634023814592,"author":{"id":"3582621734355797","authorId":"3582621734355797","name":"Terencecino","avatar":"https://static.tigerbbs.com/c10e56060ac2fd657f71b3866495a427","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582621734355797","authorIdStr":"3582621734355797"},"themes":[],"htmlText":"Yeah...good!","listText":"Yeah...good!","text":"Yeah...good!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/162932304","repostId":"1139801869","repostType":2,"repost":{"id":"1139801869","kind":"news","pubTimestamp":1623136365,"share":"https://ttm.financial/m/news/1139801869?lang=&edition=full","pubTime":"2021-06-08 15:12","market":"us","language":"en","title":"Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich","url":"https://stock-news.laohu8.com/highlight/detail?id=1139801869","media":"Motley Fool","summary":"There are better options for investors looking to profit from potential Alzheimer's disease treatmen","content":"<blockquote><b>There are better options for investors looking to profit from potential Alzheimer's disease treatments.</b></blockquote><p>The decision by the FDA to approve<b>Biogen</b>'s&nbsp;(NASDAQ:BIIB)&nbsp;Alzheimer's disease treatment aducanumab, to be marketed as Aduhelm, has given new hope to more than 5 million Americans with the disease, and their loved ones. When the Food and Drug Administration initially signaled in November that it was likely to approve the monoclonal antibody treatment, Biogen stock jumped by 43%, adding $16 billion in market capitalization to the company.</p><p>Unfortunately, thequestions surrounding the treatmentand its efficacy may leave many doctors hesitant to recommend it. Add in the expected $50,000 annual price tag and the case for Aduhelm gets even harder to make. For investors, that could prove an incentive to go looking for companies that might provide more promising Alzheimer's disease treatments.</p><p><b>CassavaSciences</b>&nbsp;(NASDAQ:SAVA)&nbsp;and&nbsp;<b>AnnovisBio</b>&nbsp;(NYSEMKT:ANVS)&nbsp;have arguably better prospects in their pipelines, and almost certainly more upside should their therapies get approved. Althoughsmall biotech stocksare risky, these two companies could turn out to be life-changing investments for some, if their potentially life-changing treatments prove effective.</p><p><b>The case for Cassava Sciences</b></p><p>While most efforts to treat Alzheimer's thus far have focused on removing the amyloid plaque or tau tangles from the brains of patients, Cassava is taking a different approach.</p><p>This $2.6 billion biotech is trying to address the root cause of those buildups instead of treating the symptoms. Its drug, simufilam, aims to restore the normal shape and function of a type of scaffolding protein in the brain. Those altered proteins, called altered filamen A (FLNA), seem necessary for the telltale plaques and tangles to form.</p><p>In phase 2 studies, participants taking simufilam demonstrated a 10% improvement from baseline on a test of cognition with no safety concerns. That was after only six months. Biogen's drug produced less benefit with a treatment duration three times longer. Cassava reported those results in February; in May, it secured another round of funding from the National Institutes of Health (NIH). NIH has been funding the company's research since 2017. That new funding will support two phase 3 trials of simufilam set to begin later this year.</p><p>Shares of Cassava Sciences may offer a better opportunity for investors than Biogen, but even its management doesn't believe that any single drug will be able to fully treat Alzheimer's disease. That said, a successful phase 3 trial would likely push the market cap of Cassava Sciences closer to where that initial jump left Biogen's. That would mean a doubling or tripling of the share price from current levels. Cassava management plans to provide additional data in July, when it will share a report on the progress of the first 50 clinical trial participants who received the drug.</p><p><b>The case for Annovis Bio</b></p><p>Annovis Bio recently produced phase 2 results showing significant cognitive improvement in Alzheimer's patients after only one month of treatment with its drug ANVS401. The drug also showed statistically significant improvement in motor function, speed, and coordination in Parkinson's patients. The trial only included 14 patients with each disease. However, those results were promising enough to send the stock up by more than 100% in a day. The improvement was significantly stronger than the one demonstrated by patients taking either simufilam or Aduhelm.</p><p>Annovis Bio's approach to treatment focuses on reducing the levels of amyloid and tau in the brain, ensuring they stay below the dangerous level that can lead to the formation of plaques and tangles. It believes its results show that ANVS401 lowers the presence of neurotoxic proteins that ultimately lead to cell death.</p><p>Founder Maria Maccecchini said that the company has many effects to measure, and expects to have data on all of them in July. Its next step will be presenting results to the FDA and launching a phase 3 study of ANVS401 in both Alzheimer's and Parkinson's. As with Cassava, additional positive data could convince Wall Street that, based on the drug's potential, the company warrants a significantly higher stock price, even after its recent climb.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 15:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/07/forget-biogen-these-2-alzheimers-drug-stocks-could/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There are better options for investors looking to profit from potential Alzheimer's disease treatments.The decision by the FDA to approveBiogen's (NASDAQ:BIIB) Alzheimer's disease treatment aducanumab...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/07/forget-biogen-these-2-alzheimers-drug-stocks-could/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","ANVS":"Annovis Bio, Inc.","SAVA":"Cassava Sciences Inc"},"source_url":"https://www.fool.com/investing/2021/06/07/forget-biogen-these-2-alzheimers-drug-stocks-could/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139801869","content_text":"There are better options for investors looking to profit from potential Alzheimer's disease treatments.The decision by the FDA to approveBiogen's (NASDAQ:BIIB) Alzheimer's disease treatment aducanumab, to be marketed as Aduhelm, has given new hope to more than 5 million Americans with the disease, and their loved ones. When the Food and Drug Administration initially signaled in November that it was likely to approve the monoclonal antibody treatment, Biogen stock jumped by 43%, adding $16 billion in market capitalization to the company.Unfortunately, thequestions surrounding the treatmentand its efficacy may leave many doctors hesitant to recommend it. Add in the expected $50,000 annual price tag and the case for Aduhelm gets even harder to make. For investors, that could prove an incentive to go looking for companies that might provide more promising Alzheimer's disease treatments.CassavaSciences (NASDAQ:SAVA) and AnnovisBio (NYSEMKT:ANVS) have arguably better prospects in their pipelines, and almost certainly more upside should their therapies get approved. Althoughsmall biotech stocksare risky, these two companies could turn out to be life-changing investments for some, if their potentially life-changing treatments prove effective.The case for Cassava SciencesWhile most efforts to treat Alzheimer's thus far have focused on removing the amyloid plaque or tau tangles from the brains of patients, Cassava is taking a different approach.This $2.6 billion biotech is trying to address the root cause of those buildups instead of treating the symptoms. Its drug, simufilam, aims to restore the normal shape and function of a type of scaffolding protein in the brain. Those altered proteins, called altered filamen A (FLNA), seem necessary for the telltale plaques and tangles to form.In phase 2 studies, participants taking simufilam demonstrated a 10% improvement from baseline on a test of cognition with no safety concerns. That was after only six months. Biogen's drug produced less benefit with a treatment duration three times longer. Cassava reported those results in February; in May, it secured another round of funding from the National Institutes of Health (NIH). NIH has been funding the company's research since 2017. That new funding will support two phase 3 trials of simufilam set to begin later this year.Shares of Cassava Sciences may offer a better opportunity for investors than Biogen, but even its management doesn't believe that any single drug will be able to fully treat Alzheimer's disease. That said, a successful phase 3 trial would likely push the market cap of Cassava Sciences closer to where that initial jump left Biogen's. That would mean a doubling or tripling of the share price from current levels. Cassava management plans to provide additional data in July, when it will share a report on the progress of the first 50 clinical trial participants who received the drug.The case for Annovis BioAnnovis Bio recently produced phase 2 results showing significant cognitive improvement in Alzheimer's patients after only one month of treatment with its drug ANVS401. The drug also showed statistically significant improvement in motor function, speed, and coordination in Parkinson's patients. The trial only included 14 patients with each disease. However, those results were promising enough to send the stock up by more than 100% in a day. The improvement was significantly stronger than the one demonstrated by patients taking either simufilam or Aduhelm.Annovis Bio's approach to treatment focuses on reducing the levels of amyloid and tau in the brain, ensuring they stay below the dangerous level that can lead to the formation of plaques and tangles. It believes its results show that ANVS401 lowers the presence of neurotoxic proteins that ultimately lead to cell death.Founder Maria Maccecchini said that the company has many effects to measure, and expects to have data on all of them in July. Its next step will be presenting results to the FDA and launching a phase 3 study of ANVS401 in both Alzheimer's and Parkinson's. As with Cassava, additional positive data could convince Wall Street that, based on the drug's potential, the company warrants a significantly higher stock price, even after its recent climb.","news_type":1,"symbols_score_info":{"ANVS":0.9,"BIIB":0.9,"SAVA":0.9}},"isVote":1,"tweetType":1,"viewCount":230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":117856143,"gmtCreate":1623132374182,"gmtModify":1634036598274,"author":{"id":"3582621734355797","authorId":"3582621734355797","name":"Terencecino","avatar":"https://static.tigerbbs.com/c10e56060ac2fd657f71b3866495a427","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582621734355797","authorIdStr":"3582621734355797"},"themes":[],"htmlText":"To the moon!","listText":"To the moon!","text":"To the moon!","images":[{"img":"https://static.tigerbbs.com/5b0809dc5235d359c365d0454a15e259","width":"1125","height":"3352"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/117856143","isVote":1,"tweetType":1,"viewCount":97,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":117851993,"gmtCreate":1623132149312,"gmtModify":1634036599931,"author":{"id":"3582621734355797","authorId":"3582621734355797","name":"Terencecino","avatar":"https://static.tigerbbs.com/c10e56060ac2fd657f71b3866495a427","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582621734355797","authorIdStr":"3582621734355797"},"themes":[],"htmlText":"Well said","listText":"Well said","text":"Well said","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/117851993","repostId":"1181466098","repostType":4,"repost":{"id":"1181466098","kind":"news","pubTimestamp":1623131805,"share":"https://ttm.financial/m/news/1181466098?lang=&edition=full","pubTime":"2021-06-08 13:56","market":"us","language":"en","title":"Clover Health Emerges As Top WallStreetBets Interest As It Outperforms AMC, BlackBerry Stocks On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1181466098","media":"benzinga","summary":"Clover Health Investments Corp emerged as the most discussed name on r/WallStreetBets, or WSB, a pop","content":"<p><b>Clover Health Investments Corp</b>&nbsp;emerged as the most discussed name on r/WallStreetBets, or WSB, a popular retail-investor-centric Reddit forum.</p><p><b>What Happened:</b>Clover Health, which operates as a Medicare Advantage insurer, attracted 1,635 mentions on the investor forum that took the limelight for a short squeeze in shares of&nbsp;<b>GameStop Corp</b>&nbsp;earlier this year.</p><p><b>BlackBerry Ltd</b>&nbsp;received 1,595 mentions on Monday night.<b>Clean Energy Fuels Corp</b>&nbsp;,<b>AMC Entertainment Holdings Inc</b>&nbsp;and GameStop attracted 1,471, 1,072, and 591 mentions respectively.</p><p>\"SPAC King\" Chamath Palihapitiya-backed Clover Health also rose tothe most-discussed stonkstatus earlier in the month. Stonks are shares favored by retail investors.</p><p>On Monday, Clover Health shares soared 32.44% in the regular session to $11.92 and rose another 8.22% in the after-hours trading to $12.90.</p><p>Other retail favorites whose shares spiked in the regular session on Monday were AMC, which shot up 14.8% to $55, Blackberry, which gained 13.78% to $15.77, and GameStop, which rose 12.74% to $280.01.</p><p><b>Why It Matters:</b>Clover Health has a short interest of 36.10% of the total float of 112.06 million, according tohighshortinterest.com, a website that tracks stocks with short interest of over 20%.</p><p>On Monday, a poster on Redditnotedthat Clover Health is “being added to the Russell index” — adding, “I believe that CLOV is about to match the uptick with the likes of AMC and GME.”</p><p>The annualreconstitutionof Russell U.S. indexes will take place after the market close on 25 June.</p><p>Clover Health features on alist of additionsto the Russell 3000 index maintained by the FTSE Russell, which tracks the performance of the largest U.S. traded stocks.</p><p>Another posterexpresseda contrarian view making a case for why he does not like the stock, citing “shady dealings” of the company’s CEO and the fact that the company is “currently burning through cash without a healthy balance sheet to hold them through which means that it is likely they will issue additional equities to stay afloat.”</p><p>The critical Reddit post also touched on a Hindenburg Research short-report that disclosed an investigation by authorities related to predatory marketing practices.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Health Emerges As Top WallStreetBets Interest As It Outperforms AMC, BlackBerry Stocks On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Health Emerges As Top WallStreetBets Interest As It Outperforms AMC, BlackBerry Stocks On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 13:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21463953/clover-health-emerges-as-top-wallstreetbets-interest-as-it-outperforms-amc-blackberry-stocks-on-mond><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clover Health Investments Corp emerged as the most discussed name on r/WallStreetBets, or WSB, a popular retail-investor-centric Reddit forum.What Happened:Clover Health, which operates as a Medicare ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21463953/clover-health-emerges-as-top-wallstreetbets-interest-as-it-outperforms-amc-blackberry-stocks-on-mond\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","BB":"黑莓","CLOV":"Clover Health Corp"},"source_url":"https://www.benzinga.com/news/21/06/21463953/clover-health-emerges-as-top-wallstreetbets-interest-as-it-outperforms-amc-blackberry-stocks-on-mond","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181466098","content_text":"Clover Health Investments Corp emerged as the most discussed name on r/WallStreetBets, or WSB, a popular retail-investor-centric Reddit forum.What Happened:Clover Health, which operates as a Medicare Advantage insurer, attracted 1,635 mentions on the investor forum that took the limelight for a short squeeze in shares of GameStop Corp earlier this year.BlackBerry Ltd received 1,595 mentions on Monday night.Clean Energy Fuels Corp ,AMC Entertainment Holdings Inc and GameStop attracted 1,471, 1,072, and 591 mentions respectively.\"SPAC King\" Chamath Palihapitiya-backed Clover Health also rose tothe most-discussed stonkstatus earlier in the month. Stonks are shares favored by retail investors.On Monday, Clover Health shares soared 32.44% in the regular session to $11.92 and rose another 8.22% in the after-hours trading to $12.90.Other retail favorites whose shares spiked in the regular session on Monday were AMC, which shot up 14.8% to $55, Blackberry, which gained 13.78% to $15.77, and GameStop, which rose 12.74% to $280.01.Why It Matters:Clover Health has a short interest of 36.10% of the total float of 112.06 million, according tohighshortinterest.com, a website that tracks stocks with short interest of over 20%.On Monday, a poster on Redditnotedthat Clover Health is “being added to the Russell index” — adding, “I believe that CLOV is about to match the uptick with the likes of AMC and GME.”The annualreconstitutionof Russell U.S. indexes will take place after the market close on 25 June.Clover Health features on alist of additionsto the Russell 3000 index maintained by the FTSE Russell, which tracks the performance of the largest U.S. traded stocks.Another posterexpresseda contrarian view making a case for why he does not like the stock, citing “shady dealings” of the company’s CEO and the fact that the company is “currently burning through cash without a healthy balance sheet to hold them through which means that it is likely they will issue additional equities to stay afloat.”The critical Reddit post also touched on a Hindenburg Research short-report that disclosed an investigation by authorities related to predatory marketing practices.","news_type":1,"symbols_score_info":{"AMC":0.9,"BB":0.9,"CLOV":0.9}},"isVote":1,"tweetType":1,"viewCount":92,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":117864911,"gmtCreate":1623131141633,"gmtModify":1634036610378,"author":{"id":"3582621734355797","authorId":"3582621734355797","name":"Terencecino","avatar":"https://static.tigerbbs.com/c10e56060ac2fd657f71b3866495a427","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582621734355797","authorIdStr":"3582621734355797"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>up up up","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>up up up","text":"$AMC Entertainment(AMC)$up up up","images":[{"img":"https://static.tigerbbs.com/05244fcc396125bcace4855cc8e6156e","width":"1170","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/117864911","isVote":1,"tweetType":1,"viewCount":180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}